Welcome to our dedicated page for Cigna Group SEC filings (Ticker: CI), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Cigna Group (NYSE: CI) files a broad range of documents with the U.S. Securities and Exchange Commission that together provide a detailed view of its operations as a global health company. These SEC filings cover its activities across Cigna Healthcare and Evernorth Health Services, including health insurance, pharmacy benefit services, specialty pharmacy, care services, and related health solutions.
On this page, you can review current and historical 10-K and 10-Q reports to understand how The Cigna Group describes its business segments, risk factors, and financial performance over time. These filings typically break out results for Evernorth Health Services, Cigna Healthcare, and Corporate and Other Operations, and they explain non-GAAP measures such as adjusted income from operations that management uses to evaluate underlying trends.
The Cigna Group also submits frequent Form 8-K reports. Recent examples include 8-K filings announcing quarterly earnings results, affirmations of full-year outlook, changes to Board committee structures, Board appointments and retirements, and the issuance of senior notes with details on interest rates, maturities, and intended use of proceeds. These current reports highlight material events such as capital markets transactions and governance changes.
Debt offerings and related agreements are documented through exhibits to 8-K filings, including underwriting agreements, supplemental indentures, and legal opinions. These materials outline the terms of senior notes and the covenants that apply to The Cigna Group’s indebtedness.
Using this page, you can access real-time updates from EDGAR alongside AI-powered summaries that explain the key points of lengthy filings in plain language. AI analysis can help you quickly identify segment performance drivers in 10-Qs and 10-Ks, interpret the implications of new debt issuances, and understand governance or committee changes disclosed in 8-Ks. You can also review any Form 4 insider transaction reports, when available, to see how directors and executives are trading CI shares.
For investors, analysts, and researchers, The Cigna Group’s SEC filings provide a structured record of its financial condition, strategic initiatives, risk disclosures, and corporate governance framework, and this page brings those documents together with tools to make them easier to interpret.
The Cigna Group reported stronger results for the quarter ended March 31, 2026, driven mainly by pharmacy operations. Total revenues rose to $68.5 billion from $65.5 billion, as pharmacy revenues increased to $54.0 billion while premiums declined after the prior-year Medicare Advantage divestiture.
Shareholders’ net income grew to $1.65 billion from $1.32 billion, with diluted EPS rising to $6.26 from $4.85. Adjusted income from operations increased to $2.06 billion (or $7.79 per diluted share) from $1.84 billion ($6.74 per share), reflecting higher contributions from both Evernorth Health Services and Cigna Healthcare.
The company continued its multi‑year Strategic Optimization Program, recording $380 million of pre‑tax charges in the quarter, mainly severance, bringing program‑to‑date costs to $1.13 billion pre‑tax. Operating cash flow was $1.13 billion, cash and cash equivalents were $7.0 billion, and long‑term debt declined to $29.4 billion. The Board declared a quarterly dividend of $1.56 per share.
The Cigna Group reported strong first quarter 2026 results with broad-based growth across its businesses and a higher full-year outlook. Total revenues were $68.5 billion for the quarter, up from $65.5 billion a year earlier, driven mainly by pharmacy-related operations. Shareholders’ net income rose to $1.65 billion, or $6.26 per share, compared with $1.32 billion, or $4.85 per share, in first quarter 2025.
Adjusted income from operations was $2.06 billion, or $7.79 per share, versus $1.84 billion, or $6.74 per share, a year ago. Evernorth Health Services generated $58.4 billion in adjusted revenues and $1.47 billion in pre-tax adjusted income, while Cigna Healthcare delivered $11.5 billion in adjusted revenues and $1.51 billion in pre-tax adjusted income with a 13.2% pre-tax margin. The company now expects full-year 2026 consolidated adjusted income from operations of at least $30.35 per share, modestly above its prior projection.
Cigna Group/The reports that Vanguard Capital Management beneficially owns 19,814,433 shares of Common Stock, representing 7.51% of the class as of 03/31/2026. The filing states Vanguard Capital Management has sole dispositive power over 19,814,433 shares and sole voting power for 2,692,364 shares. The report is signed on 04/29/2026.
The Cigna Group reported the results of its 2026 annual shareholder meeting, where 237,225,441 shares were represented out of 263,660,761 entitled to vote, a participation rate of 89.97%.
Shareholders elected all 12 director nominees and gave advisory approval to executive compensation with 201,746,941 votes for and 17,359,954 against, with 513,936 abstentions. They ratified PricewaterhouseCoopers LLP as independent registered public accounting firm for 2026 with 216,061,458 votes for and 21,030,077 against. A shareholder proposal to allow action by written consent did not pass, receiving 104,982,574 votes for and 114,173,793 against.
Cigna Group director Eric J. Foss received a grant of 782 shares of common stock on April 22, 2026. The shares were acquired at no cost as a compensation-related award and are held directly. Following this grant, Foss directly owns 36,696 shares of Cigna common stock.
McClellan Mark B. reported acquisition or exercise transactions in this Form 4 filing.
Cigna Group director Mark B. McClellan received a grant of 782 shares of common stock. The award was recorded at a price of $0.0000 per share, reflecting stock-based compensation rather than a market purchase. Following this grant, he directly holds 6,891 Cigna common shares.
Hathi Neesha reported acquisition or exercise transactions in this Form 4 filing.
Cigna Group director Neesha Hathi received a grant of 782 shares of common stock as compensation. The shares were awarded at a stated price of $0.0000 per share, indicating a non-cash grant rather than an open-market purchase. Following this award, Hathi directly holds 4,151 Cigna Group shares.
ZARCONE DONNA F reported acquisition or exercise transactions in this Form 4 filing.
Cigna Group director Donna F. Zarcone received an award of 782 shares of common stock on April 22, 2026. The grant was compensation-related, with no purchase price per share reported. Following this award, her directly owned holdings increased to 27,517 shares of Cigna common stock.
Her overall economic interest also includes cash-settled hypothetical shares tied to Cigna’s stock value, which are not shown in the share table because they are paid in cash rather than stock upon separation from service.
MAZZARELLA KATHLEEN M reported acquisition or exercise transactions in this Form 4 filing.
Cigna Group director Kathleen M. Mazzarella received an equity grant of 782 shares of Cigna common stock. The award was recorded at a price of $0.00 per share, indicating it was a compensation-related grant rather than a market purchase. After this grant, she directly holds 6,891 Cigna shares.
Kurian George reported acquisition or exercise transactions in this Form 4 filing.
Cigna Group director George Kurian received an award of 782 shares of common stock on April 22, 2026. The shares were granted at $0.00 per share, increasing his directly held position to 4,560 shares of Cigna Group common stock.
A footnote explains that his economic interest also includes hypothetical shares whose value is tied to Cigna Group stock but settled in cash upon separation from service, so these cash-settled units are not included in the reported share totals.